Acurx Pharmaceuticals, Inc. — Form 8-K Summary
Business context and reporting period
The Form 8-K reports matters approved at Acurx Pharmaceuticals’ annual meeting held June 15, 2023. The company is a Delaware pharmaceutical issuer listed on Nasdaq under the symbol ACXP. The related Certificate of Amendment to the Certificate of Incorporation was filed with the Delaware Secretary of State on June 20, 2023.
Financial metrics and liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating-performance metrics. No financial statements or financial guidance were included.
Material changes and corporate actions
- Stockholders elected David P. Luci and Jack H. Dean as Class II directors, each to serve until the 2026 annual meeting.
- Stockholders ratified CohnReznick LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Stockholders approved an amendment to the Certificate of Incorporation reflecting Delaware law provisions regarding officer exculpation. The amendment was subsequently filed on June 20, 2023.
Annual meeting voting results
| Proposal | For | Against | Other |
|---|---|---|---|
| Election of David P. Luci | 5,749,190 | — | 418,609 withheld; 2,930,682 broker non-votes |
| Election of Jack H. Dean | 5,575,112 | — | 592,687 withheld; 2,930,682 broker non-votes |
| Auditor ratification | 9,016,668 | 17,184 | 64,629 abstentions; no broker non-votes |
| Officer-exculpation amendment | 6,054,547 | 81,822 | 31,430 abstentions; 2,930,682 broker non-votes |
As of the April 24, 2023 record date, 11,671,795 common shares were outstanding and entitled to vote. Holders of 9,098,481 shares, or approximately 77.95%, were represented at the meeting, establishing a quorum.
Guidance, risks, contingencies, and unusual items
The filing contains no management guidance, outlook, liquidity warning, litigation contingency, or unusual financial item. The officer-exculpation amendment changes the company’s charter provisions but does not provide details in the filing regarding its practical financial effect.
Key facts for investors to verify
- Review the filed Certificate of Amendment to confirm the precise scope of officer exculpation.
- Confirm the continuing service and committee roles of the two elected Class II directors.
- Review subsequent filings for the company’s financial condition, cash runway, financing needs, clinical development progress, and risk factors, none of which are addressed in this 8-K.
- Note the filing’s event date of June 15, 2023 and the subsequent charter-amendment filing date of June 20, 2023.